Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy

Abstract Background This study aimed to examine the clinical characteristics of bone metastasis (BoM) in patients with non‐small cell lung cancer (NSCLC) who have an epidermal growth factor receptor (EGFR) mutation and to identify the most effective treatment strategy using EGFR–tyrosine kinase inhi...

Full description

Bibliographic Details
Main Authors: Wei‐Chun Chen, Wen‐Chien Cheng, Chieh‐Lung Chen, Wei‐Chih Liao, Chia‐Hung Chen, Hung‐Jen Chen, Chih‐Yen Tu, Chi‐Chen Lin, Te‐Chun Hsia
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Medicine
Subjects:
antiangiogenesis
bone metastasis
chemotherapy
denosumab
epidermal growth factor receptor
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.7152

Internet

https://doi.org/10.1002/cam4.7152

Similar Items